You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》華檢醫療(01931.HK)料「兩票制」影響不大IVD行業推行有困難
阿思達克 06-28 18:00

中國體外診斷(IVD)產品分銷商華檢醫療(01931.HK)總經理林賢雅出席記者會時表示,「兩票制」議題在醫療行業較熱門,他解釋「兩票制」的意思是在價值鏈中限制最多發出兩張發票,第一張發票由製造商發給分銷商,第二張發票由分銷商發給醫院及醫療機構。

他指出早前收購的威士達為醫療保健公司希森美康的全國分銷商並擁獨家分銷權,公司的中國法律顧問認為在相關情況下威士達可能被視作製造商,故希森美康向威士達的發票不會被計為第一張發票,所以預期「兩票制」對集團影響不大。

首席營運官梁景新補充,公司分銷IVD產品的大部分區域當局尚未將「兩票制」應用於IVD產品行業,認為要在行業內推行相對較困難,留意到有一些省份想推動但亦未能成功。

主席兼行政總裁何鞠誠指出,未來公司發展有三個方向,一方面繼續增加威士達的全國覆蓋,另一方面要繼續深耕上海市場,以及加強品牌的研發及投入。首席財務官周傳波指出,公司部分募集資金亦將投入在自有品牌上,冀相關業務可助提升業績。另外在產品定價方面,他指出公司會考慮來貨價、市場接納程度及競爭等,公司策略包括向下游傳遞、增加收入來源及改善產品組合等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account